Biohaven Achieves Orphan Drug Designation for ALS Drug Candidate

The FDA has granted an orphan drug designation to Biohaven’s drug candidate BHV-0223, a developing treatment for amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease.

BHV-0223 is administered under the tongue as a dissolving tablet.

Biohaven plans to conduct a bioequivalence study for the candidate in 2017.